Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia

Ueno, T.; Zenitani, M.; Yamanaka, H.; Tanaka, N.; Uehara, S.; Tazuke, Y.; Bessho, K.; Okuyama, H.

doi:https://doi.org/10.1016/j.transproceed.2016.02.011

Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia

Ueno, T.; Zenitani, M.; Yamanaka, H. et al.

Transplantation Proceedings, 2016, 48(4), 1095-1099

Number of Access:1,051（2025-07-22 21:54 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/98564

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available
TransplantProc_48_4_1095_abstract	pdf	None	68.1 KB	13	2024.12.06
TransplantProc_48_4_1095_manuscript	pdf	None	318 KB	21	2024.12.06
TransplantProc_48_4_1095_figure	pdf	None	654 KB	13	2024.12.06
TransplantProc_48_4_1095_table	pdf	None	136 KB	13	2024.12.06

Creative Commons : Attribution - NonCommercial - NoDerivatives

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia
Creator	NRID 1000010456957 1000010456957 ORCID 0000-0002-4639-8814 0000-0002-4639-8814 researchmap permalink ueno-pedsurg ueno-pedsurg Scopus Author ID 21743992300 21743992300 CreatorName Ueno, T.
	NRID 1000040643531 1000040643531 CreatorName Zenitani, M.
	NRID 1000070467570 1000070467570 CreatorName Yamanaka, H.
	NRID 1000020456958 1000020456958 CreatorName Tanaka, N.
	NRID 1000000448060 1000000448060 CreatorName Uehara, S.
	NRID 1000010397698 1000010397698 researchmap permalink yukotazuke-osaka yukotazuke-osaka Scopus Author ID 7006109798 7006109798 ORCID 0000-0002-8335-0414 0000-0002-8335-0414 CreatorName Tazuke, Y.
	NRID 1000080423169 1000080423169 researchmap permalink KazuBe KazuBe CreatorName Bessho, K.
	NRID 1000030252670 1000030252670 researchmap permalink okuyamahiroomi okuyamahiroomi Scopus Author ID 35496082300 35496082300 ORCID 0000-0002-1347-282X 0000-0002-1347-282X CreatorName Okuyama, H.
Description	Ueno T., Zenitani M., Yamanaka H., et al. Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia. Transplantation Proceedings 48, 1095 (2016); https://doi.org/10.1016/j.transproceed.2016.02.011.
Abstract	Background: Pediatric living donor liver transplant (LDLT) patients sometimes develop graft fibrosis after non-recurrent diseases such as biliary atresia (BA). Donor-specific antibodies (DSA) have recently been shown to play a possible role in graft damage after liver transplantation. We report the impact of DSA on pediatric LDLT for BA patients. Methods: Patients under age 18 years who received LDLT for BA at our institution and who had at least 5 years' follow-up were identified, and 23 were eventually enrolled in this study. Pathological findings were assessed with the use of the last available biopsy. Patients were divided into 2 groups, DSA-positive and DSA-negative. Graft fibrosis after LDLT was assessed according to DSA groups. Results: The mean patient age at transplant was 2.6 years. The mean time to the last available biopsy after LDLT was 8.2 years (4.8-15.6 years); 6 patients (26%) showed no fibrosis, whereas fibrosis was graded as F1, F2, or F3 in 8 patients (35%), 8 patients (35%), and 1 patient, respectively. DSA were observed in 12 patients (52%). Moderate graft fibrosis (F2 and F3) was found in 7 (58%) of the DSA-positive group, but only 2 (18%) of the DSA-negative group, showing a statistically significant difference (P <.05). Pre-transplant cross-matching was performed in 17 patients. The 2 patients with a positive cross-match were DSA-positive. Six cross-match-negative patients developed de novo DSA after LDLT. Conclusions: Graft fibrosis was observed after LDLT for BA during long-term follow-up, more commonly in DSA-positive patients. DSA may play a role in fibrosis formation.
Conference Information	Conference Name Congress of the Asian Society of Transplantation Conference Sequence 14 Conference Date August 23rd to August 25th, 2015 Conference Venue Suntec Singapore Convention and Exhibition Centre Conference Place Singapore Conference Country Singapore
Publisher	Elsevier USA
Source Title	Transplantation Proceedings
Volume (Issue)	48(4)
Page	1095-1099
Date of Issued	2016-05-01
Language	English
Handle URL	https://hdl.handle.net/11094/98564
PISSN	00411345
eISSN	18732623
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1016/j.transproceed.2016.02.011
Access Rights	open access
CopyRight	©2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
oaire:version	Accepted Manuscript
Category	会議発表論文 Conference Paper

Resource Type	conference paper
Local Type	Conference Paper
DCTERMS.bibliographicCitation	Transplantation Proceedings. 2016, 48(4), p. 1095-1099
DC.title	Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia
DC.creator	Ueno, T.
	Zenitani, M.
	Yamanaka, H.
	Tanaka, N.
	Uehara, S.
	Tazuke, Y.
	Bessho, K.
	Okuyama, H.
DC.publisher	Elsevier USA
DC.language' scheme='DCTERMS.RFC1766	English
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2016-05-01
DC.identifier	https://doi.org/10.1016/j.transproceed.2016.02.011
DC.description	Ueno T., Zenitani M., Yamanaka H., et al. Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia. Transplantation Proceedings 48, 1095 (2016); https://doi.org/10.1016/j.transproceed.2016.02.011.
DCTERMS.abstract	Background: Pediatric living donor liver transplant (LDLT) patients sometimes develop graft fibrosis after non-recurrent diseases such as biliary atresia (BA). Donor-specific antibodies (DSA) have recently been shown to play a possible role in graft damage after liver transplantation. We report the impact of DSA on pediatric LDLT for BA patients. Methods: Patients under age 18 years who received LDLT for BA at our institution and who had at least 5 years' follow-up were identified, and 23 were eventually enrolled in this study. Pathological findings were assessed with the use of the last available biopsy. Patients were divided into 2 groups, DSA-positive and DSA-negative. Graft fibrosis after LDLT was assessed according to DSA groups. Results: The mean patient age at transplant was 2.6 years. The mean time to the last available biopsy after LDLT was 8.2 years (4.8-15.6 years); 6 patients (26%) showed no fibrosis, whereas fibrosis was graded as F1, F2, or F3 in 8 patients (35%), 8 patients (35%), and 1 patient, respectively. DSA were observed in 12 patients (52%). Moderate graft fibrosis (F2 and F3) was found in 7 (58%) of the DSA-positive group, but only 2 (18%) of the DSA-negative group, showing a statistically significant difference (P <.05). Pre-transplant cross-matching was performed in 17 patients. The 2 patients with a positive cross-match were DSA-positive. Six cross-match-negative patients developed de novo DSA after LDLT. Conclusions: Graft fibrosis was observed after LDLT for BA during long-term follow-up, more commonly in DSA-positive patients. DSA may play a role in fibrosis formation.
DC.rights	©2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
DC.format	98564
citation_title	Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia
citation_author	Ueno, T.
	Zenitani, M.
	Yamanaka, H.
	Tanaka, N.
	Uehara, S.
	Tazuke, Y.
	Bessho, K.
	Okuyama, H.
citation_publisher	Elsevier USA
citation_language	English
citation_date	2016-05-01
citation_journal_title	Transplantation Proceedings
citation_volume	48
citation_issue	4
citation_firstpage	1095
citation_lastpage	1099
citation_doi	https://doi.org/10.1016/j.transproceed.2016.02.011
citation_public_url	https://hdl.handle.net/11094/98564

Impact of Donor-Specific Antibodies on Graft Fibrosis after Pediatric Living Donor Liver Transplantation for Biliary Atresia

Link to primary information

Item Information

Show details